Idera Pharmaceuticals Inc  

(Public, NASDAQ:IDRA)   Watch this stock  
Find more results for IDRA
3.57
+0.14 (4.23%)
Mar 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.43 - 3.61
52 week 1.93 - 5.48
Open 3.43
Vol / Avg. 1.34M/2.69M
Mkt cap 403.59M
P/E     -
Div/yield     -
EPS -0.47
Shares 117.84M
Beta 2.65
Inst. own 25%
May 11, 2015
Q1 2015 Idera Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 12, 2015
Q4 2014 Idera Pharmaceuticals Inc Earnings Release
Mar 2, 2015
Idera Pharmaceuticals Inc at Cowen Health Care Conference
Feb 25, 2015
Idera Pharmaceuticals, Inc. at RBC Capital Markets Healthcare Conference - Webcast
Jan 15, 2015
Idera Pharmaceuticals Inc at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -595900.00% -52934.25%
Operating margin -596450.00% -53084.93%
EBITD margin - -52810.96%
Return on average assets -85.32% -87.53%
Return on average equity -106.27% -120.75%
Employees 45 -
CDP Score - -

Address

167 Sidney St
CAMBRIDGE, MA 02139-4237
United States - Map
+1-617-6795500 (Phone)
+1-617-6795592 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates. The Company is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors (TLRs). It is also evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA. During the year ended December 31, 2011, the Company collaborated with Merck Sharp & Dohme Corp., for the use of agonists of TLRs 7, 8, and 9 as vaccine adjuvants for cancer, infectious diseases, and Alzheimer�s disease. In November 2011, the Company reacquired rights to IMO-2055 from Merck KGaA, Darmstadt, Germany, its former collaborator.

Officers and directors

James A. Geraghty Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Vincent J. Milano President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Youssef El Zein Independent Vice Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Louis J. Arcudi III Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary
Age: 53
Bio & Compensation  - Reuters
Louis Brenner M.D. Senior Vice President, Chief Medical Officer
Age: 44
Bio & Compensation  - Reuters
Robert Clayton Fletcher Senior Vice President - Business Development and Strategic Planning
Age: 51
Bio & Compensation  - Reuters
Robert A. Doody Jr. Vice President - Investor Relations and Corporate Communications
Bio & Compensation  - Reuters
William S. Reardon CPA Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Sudhir Agrawal Director, President of Research
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Julian C. Baker Director
Age: 49
Bio & Compensation  - Reuters